Please login to the form below

Not currently logged in
Email:
Password:

Minoyrx Therapeutics appoints chief medical officer

Dr Uwe Meya joins from Lupin Atlantis Holdings

Minoryx Therapeutics Dr Uwe MeyaSpanish orphan disease specialist Minoryx Therapeutics has appointed Dr Uwe Meya as its new chief medical officer.

Dr Meya brings over 30 years of research and development experience to the firm, with a background as a neurologist and psychiatrist.

He joins the Barcelona-based drug development company from Lupin Atlantis Holdings, where he oversaw its clinical strategy and implementation of studies in various therapeutic areas, including neurodegenerative disorders.

Prior to this, Dr Meya was head of phase I and II clinical studies in neurodegenerative disorders at Synosia Therapeutics, and served as head of research portfolio management and clinical research and licensing liaison manager in CNS at Roche.

He also has leadership experience working at Novartis in CNS clinical development, at Knoll as head of clinical development, and as a medical advisor and the head of clinical psychiatry at Schering.

Marc Martinell, chief executive officer of Minoryx Therapeutics, said: “We are delighted to welcome Dr Meya as our chief medical officer.

“Hi wealth of expertise in CNS-related research will help us significantly in moving forward the clinical development of our lead candidate MIN-102. He will also support the further development of our pipeline in orphan diseases.”

24th June 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics